SciNeuro
Rockville
About SciNeuro
SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged from discovery to clinical development by addressing three key disease-driving mechanisms of neurodegeneration – neurovascular inflammation, proteinopathy, and immune response. The company aims to develop disease-modifying treatment options for Alzheimer’s disease, Parkinson’s disease, and other devastating CNS diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $158.0M
- Last round: Series Unknown (Dec 2025)
- Website: scineuro.com
Industries & Categories
Biopharma, Biotechnology, Neuroscience
Social Profiles
Canonical: https://fsome.com/organization/scineuro-61610 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.